Exelixis: Undervalued And Unloved

Nov. 07, 2022 7:08 AM ETExelixis, Inc. (EXEL)16 Comments

Summary

  • Today, we circle back on mid-cap oncology concern Exelixis, Inc. which just delivered another quarter of rock-solid results.
  • Its blockbuster drug CABOMETYX continues to show good growth and the company is sitting on a massive cash hoard.
  • What is the best way to trade this unloved value stock? An investment analysis follows in the paragraphs below.
  • Looking for a portfolio of ideas like this one? Members of The Biotech Forum get exclusive access to our subscriber-only portfolios. Learn More »

Unrecognizable doctor caring highlighted red handrawn Bladder and Kidneys. Medical illustration, template, science mockup.

mi-viri

"Science may have found a cure for most evils; but it has found no remedy for the worst of them all -- the apathy of human beings."― Helen Keller

Mid-cap oncology name Exelixis, Inc. (NASDAQ:EXEL) delivered another quarter of

Stock Chart

Seeking Alpha

Q3'22 Total Revenues

November Company Presentation

CABOMETYX Business Summary - #1 TKI in RCC

November Company Presentation

Fiscal Year 2022 Financial Guidance *

November Company Presentation

Enhancing Our Clinical Pipeline through Business Development

November Company Presentation

Cabozantinib Poised for Continued Growth Through Lifecycle Expansion

November Company Presentation

COSMIC-313: Phase 3 Pivotal Trial of Cabozantinib + Nivolumab + Ipilimumab in 1L RCC

November Company Presentation

CONTACT Phase 3 Pivotal Trials Evaluating Cabozantinib + Atezolizumab

November Company Presentation

Stock Chart

Seeking Alpha

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.

This article was written by

Bret Jensen profile picture
45.84K Followers
Finding tomorrow's big winners in the lucrative biotech sector

Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha. It is the fourth most subscribed to investment service offered through the Marketplace on SeekingAlpha.com. Our service offers a model-20 stock portfolio as well as the most active Live Chat on the Marketplace. This is where scores of seasoned biotech investors trade news and investment ideas back and forth throughout the trading day.

• • •

Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.

• • •

Learn more about Bret Jensen's Marketplace Offerings:

The Insiders Forum | The Biotech Forum | Busted IPO Forum

Disclosure: I/we have a beneficial long position in the shares of EXEL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (16)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.